Compositions for the treatment of gastrointestinal inflammation

Abstract

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Description

CROSS-REFERENCE[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 987,720, filed Nov. 13, 2007; U.S. Provisional Application No. 61 / 012,012, filed Dec. 6, 2007; U.S. Provisional Application No. 61 / 015,998, filed Dec. 21, 2007; U.S. Provisional Application No. 61 / 019,818, filed Jan. 8, 2008; U.S. Provisional Application No. 61 / 034,941, filed Mar. 7, 2008; U.S. Provisional Application No. 61 / 035,348, filed Mar. 10, 2008; U.S. Provisional Application No. 61 / 054,103, filed May 16, 2008; U.S. Provisional Application No. 61 / 054,104, filed May 16, 2008; U.S. Provisional Application No. 61 / 054,105, filed May 16, 2008; U.S. Provisional Application No. 61 / 054,106, filed May 16, 2008; U.S. Provisional Application No. 61 / 054,107, filed May 16, 2008; and U.S. Provisional Application No. 61 / 090,658, filed Aug. 20, 2008, which applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Esophageal inflammation disorders are gaining increased reco...

AI Technical Summary

Benefits of technology

[0007]In certain embodiments, the present invention is directed to methods and pharmaceutical compositions for treating, preventing or alleviating the symptoms of and/or inflammation associated with inflammatory diseases involving the gastrointestinal tract, including the esophagus, stomach and/or digestive tract. Provided herein are methods of treating, preventing or alleviating, for example, esophageal inflammation in an individual. In certain embodiments, these methods comprise orally administering to said individual a corticosteroid in association with at least one additional active agent. In some embodiments, provided herein is a pharmaceutical composition comprising a corticosteroid and at least one additional active agent. In specific embodiments, the at least one additional active agent is an agent that treats, prevents, or alleviates the symptoms of and/or inflammation associated with

Problems solved by technology

Symptoms of EoE include, for example, abdominal pain, chest pain, choking, difficulty swallowing, failure to thrive, nausea, reflux not relieved by standard anti-flux therapy, skin rash or hives, vomiting, and weight loss.

The common occurrence regarding misdiagnosis of EoE for GERD often results in delayed treatment for patients with EE or EoE.

Long term systemic steroid therapy can result in significant secondary side effects on growth and bone development.

Although treatment with anti-IL-5 monoclonal antibody has been reporte

Images